<DOC>
	<DOCNO>NCT02221388</DOCNO>
	<brief_summary>To compare oral bioavailability rate absorption two different formulation BI 671800 HEA ( choline salt ) tablets 200 mg , one enteric coating ( EC ) one without EC , versus 2 x 100 mg BI 671800 ED ( ethylenediamine salt ) capsule . Both BI 671800 HEA formulation investigate concern food effect one two BI 671800 HEA formulation identify interim pharmacokinetic analysis investigate concern dose proportionality 50 mg .</brief_summary>
	<brief_title>Relative Bioavailability Different Formulations BI 671800 Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 21 50 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) Intake drug within one month le 10 halflives respective drug prior first study drug administration Participation another trial investigational drug within 2 month prior administration trial Smoker ( 10 cigarette 3 cigar 3 pipe daily ) Alcohol abuse ( average consumption 20 g/day female 30 g/day male ) Drug abuse Blood donation ( 100 mL within four week prior day 1 visit 2 ) Any laboratory value outside reference range clinical relevance , especially repeat alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyltransferase ( GGT ) , alkaline phosphatase ( ALP ) total bilirubin upper limit normal ( ULN ) screen resolve dosing . Inability comply dietary regimen trial site Unwilling avoid excessive sunlight exposure Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day prior administration trial , CYP2C8 substrates amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone repaglinide CYP2C9 warfarin , tolbutamide , phenytoin , losartan , acenocoumarol within 1 month six half life ( whichever great ) . A marked baseline prolongation QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) For female subject childbearing potential : Positive pregnancy test , pregnancy plan become pregnant study within 2 month study completion No adequate contraception study include three month first dose 2 month study completion , e.g . follow : implant , injectables , combine hormonal contraceptive , intrauterine device , surgical sterilisation ( include hysterectomy ) . In addition , also barrier method ( e.g . condom ) require , female surgically sterilise . Lactation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>